Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com - JMP Securities has reiterated its Market Outperform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ:INO), according to a research note published Wednesday. The target represents significant upside from the current price of $1.49, though InvestingPro analysis indicates the stock’s overall financial health score remains weak at 1.71 out of 5.
The firm noted that Inovio remains on track to complete its Biologics License Application (BLA) by the end of 2025, with current funding expected to sustain operations into the second quarter of 2026. The company reported second-quarter results that aligned with both JMP’s and consensus estimates.
Inovio ended the quarter with $47.5 million in cash and added $22.5 million net in July. The company has completed the design verification testing for INO-3107 needed to update its Investigational New Drug (IND) application and advance to the BLA submission.
The pharmaceutical company has requested a rolling submission from the FDA and expects agency acceptance this month. JMP views INO-3107 as "highly likely to gain approval" based on existing clinical data.
JMP maintains its positive outlook despite the potential approval of a competitor product from Precigen (NASDAQ:PGEN) which has a Prescription Drug User Fee Act (PDUFA) date of August 27.
In other recent news, Inovio Pharmaceuticals reported a significant reduction in losses for the second quarter of 2025. The company managed to decrease its operating expenses by 31%, which contributed to cutting its net loss per share by nearly half. These financial results come amidst a challenging market environment, demonstrating the company’s efforts to manage costs effectively. This development was positively received by investors, as reflected in the aftermarket trading activity. Despite the financial challenges, Inovio’s performance indicates a potentially stabilizing trajectory. The report did not include any updates on mergers or acquisitions. Additionally, there were no recent analyst upgrades or downgrades mentioned. These developments highlight Inovio’s current financial strategy and its impact on investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.